Slow Q1 For Baxter, But Board Remains Confident Of Turnaround
Executive Summary
Baxter International recorded slight revenue increases during quarter one of 2021, with sales still impacted by COVID-19. Its board remains optimistic , pointing towards new product releases and “operational strength” as redeeming factors.
You may also be interested in...
BD Expects Alaris Infusion Pump To Return To US Market Next Year
The company stopped shipping Alaris in early 2020 after the FDA requested a new 510(k) for modifications and the device has been the subject of several recalls since then.
Moving Pharma Execs Out Of The Shadows Is Key To Building Public Trust
2024 Rising Leader, Jack O’Meara, says the industry must ‘promote personalities’ when building new biotech businesses to gain the trust of investors and the public.
Deals Shaping The Industry, February 2024
An interactive look at pharma, medtech, and diagnostics deals made during February 2023. Data courtesy of Biomedtracker.